Illustrating Potential Efficiency Gains From Using Cost-Effectiveness Evidence To Reallocate Medicare Expenditures For Medical Technology

Published May 17, 2013
Boston, MA, USA - Researchers from the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center have illustrated potential health gains from using cost-effectiveness evidence to inform Medicare resource allocation for medical technology.  Focusing on interventions evaluated through Medicare’s National Coverage Determination process – reserved for ‘big-ticket’ items, i.e., interventions deemed to have a significant impact on Medicare – the researchers estimated potential health gains and cost-savings from using cost-effectiveness evidence to reallocate expenditures. In the study, “Illustrating Potential Efficiency Gains from Using Cost-Effectiveness Evidence to Reallocate Medicare Expenditures,“ the researchers used quality adjusted life years (QALYs), which account for quantity and quality of life, to measure health gains.  They found that simply increasing utilization of cost-saving technologies that are more effective and no more costly than available alternatives adds 270,000 QALYs, while accumulating $12.9 billion of savings. When reallocating expenditures from less cost-effective interventions, e.g., ventricular assist devices for heart failure, or pancreas transplantation, to more cost-effective interventions, e.g., cardiac rehabilitation programs, or ultrasound image guidance for breast cancer screening, Medicare beneficiaries gained 1.8 million QALYs in aggregate terms, approximately 0.17 QALYs per affected individual. “Medicare has been resistant to using cost-effectiveness information,” said lead researcher, James Chambers, PhD, “But our analysis shows that substantial potential health benefits and cost-savings are possible if the program adopted cost-effectiveness evidence.”

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

Advancing the Economics of Mental Health: A Global Perspective

Mar 12, 2025

Value in Health, the official journal of ISPOR announced the publication of a special themed section of research papers exploring mental health economics, highlighting impacts on caregivers, productivity, and interventions’ cost-effectiveness.

Generative AI Set to Reshape Health Technology Assessment, ISPOR Report Finds

Feb 11, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of an ISPOR Working Group Report that provides an introduction to the uses of generative artificial intelligence (AI) in health technology assessment (HTA).

ISPOR Tackles Health Disparities with New Research Primer

Jan 22, 2025

ISPOR announced today the publication of a report from the ISPOR Health Equity Research Special Interest Group intended to establish key concepts for conducting health equity research that enables investigators to examine—and ultimately reduce—unfair social inequities in health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×